Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Rofecoxib not likely to delay progression from mild cognitive impairment
July 12th, 2005
Rofecoxib treatment is not likely to delay the progression from mild cognitive impairment (MCI) to Alzheimer disease (AD). "Inflammatory mechanisms have been implicated" in AD, "and might be mediated via the COX-2 enzyme," scientists in the United States explained. "Previous studies with the selective COX-2 inhibitors, rofecoxib and celecoxib, have shown that they do not alter the progression of AD," noted L.J. Thal and colleagues at Merck Research Laboratories. They "conducted a double-blind study to investigate whether rofecoxib could delay a diagnosis of AD" in MCI patients, "a group with an expected annual AD diagnosis rate of 10%-15%." ...
Source: Science Letter (2005-07-12)
|
